Riluzole therapy in Huntington's disease (HD)
β Scribed by H. Diana Rosas; Walter J. Koroshetz; Bruce G. Jenkins; Y. Iris Chen; Douglas L. Hayden; M. Flint Beal; Merit E. Cudkowicz
- Publisher
- John Wiley and Sons
- Year
- 1999
- Tongue
- English
- Weight
- 40 KB
- Volume
- 14
- Category
- Article
- ISSN
- 0885-3185
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Huntington's disease (HD) is an autosomal dominant disease characterized by motor disturbance, cognitive loss and psychiatric manifestations, starting between the fourth and the fifth decade, followed by death within 10-20 years of onset of the disease. The disease-causing mutation is an expansion o
Two brothers with clinically definite adult Huntington's disease developed disabling myoclonus years after the first signs of the disease. Their electroencephalograms were consistent with a primary generalized epilepsy, although neither man had seizures. The myoclonus was controlled with valproic ac